All Stories

  1. COVID-19 vaccinations in adults and evaluation of cardiovascular events: critical methodological issues
  2. Insulin Resistance with Associated Hyperinsulinemia as a Cause of the Development and Worsening of Heart Failure
  3. Autoantibodies Targeting G-Protein-Coupled Receptors and RAS-Related Molecules in Post-Acute COVID Vaccination Syndrome: A Retrospective Case Series Study
  4. Chronically Increased Levels of Circulating Insulin Secondary to Insulin Resistance: A Silent Killer
  5. Insulin Resistance/Hyperinsulinemia as an Independent Risk Factor That Has Been Overlooked for Too Long
  6. Insulin Resistance/Hyperinsulinemia, Neglected Risk Factor for the Development and Worsening of Heart Failure with Preserved Ejection Fraction
  7. Insulin resistance/hyperinsulinemia: an important cardiovascular risk factor that has long been underestimated
  8. A case of adverse reaction to booster dose of COVID-19 vaccination: could D-dimer elevation suggest increased clotting risk?
  9. The Negative Impact of Insulin Resistance/Hyperinsulinemia on Chronic Heart Failure and the Potential Benefits of Its Screening and Treatment
  10. Editorial: Methods in general cardiovascular medicine
  11. A Descriptive Review of the Action Mechanisms of Berberine, Quercetin and Silymarin on Insulin Resistance/Hyperinsulinemia and Cardiovascular Prevention
  12. Early Multi-Target Treatment of Mild-to-Moderate COVID-19, Particularly in Terms of Non-Steroidal Anti-Inflammatory Drugs and Indomethacin
  13. COVID-19 Medical and Pharmacological Management in the European Countries Compared to Italy: An Overview
  14. A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Management of Mild-to-Moderate Symptomatic COVID-19
  15. Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis of Early COVID-19 and Treated at Home Within 3 Days or After 3 Days of Symptom Onset with Prescribed and Non-Prescribed Treatments Between Novembe...
  16. Home pharmacological therapy in early COVID‐19 to prevent hospitalization and reduce mortality: Time for a suitable proposal
  17. Sustained High D-Dimer in Outpatients Who Have Recovered from Mild to Moderate Coronavirus Disease 2019 (COVID-19)
  18. COVID-19: Off-label therapies based on mechanism of action while waiting for evidence-based medicine recommendations
  19. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled trial
  20. Efficacy of sildenafil in HIV-related pulmonary arterial hypertension
  21. Response to letter by Wang Q et al. regarding article “Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension”
  22. Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension
  23. Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: Case report and review of the literature
  24. Effects of a nutraceutical combination on left ventricular remodeling and vasoreactivity in subjects with the metabolic syndrome
  25. Reply:
  26. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome
  27. Insulin resistance: Is it time for primary prevention?
  28. The Importance of Tricuspid Regurgitation and Right Ventricular Overload in ICD/CRT Recipients: Beside the Left, beyond the Left
  29. Endocrine Alterations Are the Main Determinants of Cardiac Remodelling in Restrictive Anorexia Nervosa
  30. A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
  31. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study
  32. Letter by Fazio and Carlomagno Regarding Article, “Heart Rate Predicts Outcomes in an Implantable Cardioverter-Defibrillator Population”
  33. Thyroid Hormones and Cardiovascular System: From Bench to Bedside
  34. Late Onset of Hypoxemia Due to a Pulmonary Arteriovenous Malformation During Selective Estrogen Receptor Modulator Therapy
  35. Cardiovascular and metabolic effects of Berberine
  36. Efficacy and safety of valsartan plus hydroclorothiazide for high blood pressure
  37. Long term combination treatment for severe idiopathic pulmonary arterial hypertension
  38. Usefulness of NT-proBNP in the assessment of patients with aortic or mitral regurgitation
  39. Growth Hormone Deficiency in Patients with Chronic Heart Failure and Beneficial Effects of Its Correction
  40. The GH/IGF-1 Axis and Heart Failure
  41. Myocarditis and dilated cardiomyopathy: possible connections and treatments
  42. Effects of Growth Hormone on Exercise Capacity and Cardiopulmonary Performance in Patients with Chronic Heart Failure
  43. Prehypertension and Elevated Risk of Cardiovascular Disease: Physiopathologic Mechanisms
  44. Association between post-ischemic forearm blood flow and blood pressure response to maximal exercise in well trained healthy young men
  45. Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension
  46. Aerobic exercise performance correlates with post-ischemic flow-mediated dilation of the brachial artery in young healthy men
  47. Tadalafil in Primary Pulmonary Arterial Hypertension
  48. Long-term efficacy of doxazosin plus atenolol in the management of severe and sustained arterial hypertension and reversibility of the cardiac damage induced by chronic cathecolamine excess. A case report in a young girl with recurrent, functioning par...
  49. Myocardial contractility and total arterial stiffness in patients with overt hyperthyroidism: acute effects of beta1-adrenergic blockade
  50. Peak exercise oxygen uptake and left ventricular systolic and diastolic function and arterial mechanics in healthy young men
  51. Effects of Thyroid Hormone on the Cardiovascular System
  52. Hyperthyroidism, Subclinical
  53. Subclinical Hypothyroidism and Cardiovascular Risk
  54. Subclinical Thyroid Dysfunction and the Heart
  55. Reactive hyperemia and cardiovascular performance in athletes regularly trained
  56. Prospective Evaluation of Hypertensive Patients with Carotid Kinking and Coiling: An Ultrasonographic 7-Year Study
  57. Cardiovascular Safety of Acute Recombinant Human Thyrotropin Administration to Patients Monitored for Differentiated Thyroid Cancer
  58. The importance of using strict inclusion criteria in subclinical hypothyroid studies
  59. Effects of Subclinical Thyroid Dysfunction on the Heart
  60. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study
  61. Patients with Subclinical Cushing’s Syndrome due to Adrenal Adenoma Have Increased Cardiovascular Risk
  62. Subclinical Hypothyroidism and Cardiac Function
  63. Supraphysiological Doses of GH Induce Rapid Changes in Cardiac Morphology and Function
  64. Effects of Thyroid Hormone on Cardiac Function - The Relative Importance of Heart Rate, Loading Conditions, and Myocardial Contractility in the Regulation of Cardiac Performance in Human Hyperthyroidism
  65. Mortality in elderly patients with subclinical hyperthyroidism
  66. Growth hormone corrects vascular dysfunction in patients with chronic heart failure
  67. Impact of Hyperthyroidism and Its Correction on Vascular Reactivity in Humans
  68. Does the Growth Factor Approach Have a Future in the Treatment of Human Heart failure?
  69. Endogenous Subclinical Hyperthyroidism Affects Quality of Life and Cardiac Morphology and Function in Young and Middle-Aged Patients*
  70. Endogenous Subclinical Hyperthyroidism Affects Quality of Life and Cardiac Morphology and Function in Young and Middle-Aged Patients
  71. Growth hormone and cardiac function
  72. The role of the GH-IGF-I axis in the regulation of myocardial growth: from experimental models to human evidence
  73. Cardiovascular Effects of Short-Term Growth Hormone Hypersecretion
  74. Heart Failure: Potential Benefit of Growth Hormone Therapy
  75. A Direct Role for the Macrophage Low Density Lipoprotein Receptor in Atherosclerotic Lesion Formation
  76. Left Ventricular Diastolic Dysfunction in Patients with Subclinical Hypothyroidism
  77. Left Ventricular Diastolic Dysfunction in Patients with Subclinical Hypothyroidism
  78. Growth Hormone and the Heart
  79. Growth hormone as a potential future therapy for congestive heart failure
  80. Growth Hormone in Heart Failure
  81. Cardiac Effects of Growth Hormone in Physiology and in Heart Failure
  82. Doxorubicin‐induced cardiomyopathy treated with carvedilol
  83. Reentrant Atrioventricular Nodal Tachycardia Induced by Levothyroxine
  84. Sympathetic deactivation by growth hormone treatment in patients with dilated cardiomyopathy
  85. Increased Arterial Intima-Media Thickness in Childhood-Onset Growth Hormone Deficiency
  86. Prevalence of Carotid Kinking and Coiling in a Population at Risk
  87. Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine
  88. Cardiovascular aspects in acromegaly: Effects of treatment
  89. A Preliminary Study of Growth Hormone in the Treatment of Dilated Cardiomyopathy
  90. Long-term growth hormone deficiency as a cause of cardiomyopathy and its reversibility with specific replacement therapy
  91. Cardiac performance: Growth hormone enters the race
  92. Impairment of lung volumes and respiratory muscle strength in adult patients with growth hormone deficiency
  93. Optimal determination of right ventricular filling dynamics in systemic hypertension
  94. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta- blockade
  95. Pacemaker Malfunction Due to Subcutaneous Emphysema
  96. Growth Hormone and the Heart
  97. Growth hormone and the heart
  98. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement
  99. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly
  100. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine
  101. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses
  102. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency
  103. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly
  104. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine
  105. Platelet Aggregability in Patients with a VVI Pacemaker
  106. Evidence for biventricular involvement in acromegaly: a Doppler echocardiographic study
  107. Capillary Blood Flow to the Skin of Forearm in Cirrhosis
  108. Influence of atenolol on the relationship between heart rate and qt interval in patients with exercise‐induced myocardial ischemia
  109. Pacemaker Malfunction Due to Subcutaneous Emphysema — A Case Report
  110. Evaluation, by Noninvasive Methods, of the Effects of Acute Loss of Thyroid Hormones on the Heart
  111. Follow‐Up of a Respiratory Rate Modulated Pacemaker
  112. Fourier Analysis in Patients with Different Pacing Modes
  113. Efficacy of Ticlopidine in the Prevention of Thromboembolic Events in Patients with VVI Pacemakers
  114. Cardiac function and sympathetic activity in young diabetics
  115. A prospective randomized trial of doxorubicinversus idarubicin in the treatment of advanced breast cancer
  116. Atenolol and Amiodarone: A Comparative Study of Their Anti-Ischaemic Effect
  117. Bisoprolol in the treatment of angina pectoris: a double blind comparison with verapamil
  118. Indapamide and atenolol in the treatment of hypertension: double-blind comparative and combination study
  119. Obesity and cardiac function.